[go: up one dir, main page]

AR020054A1 - COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS - Google Patents

COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS

Info

Publication number
AR020054A1
AR020054A1 ARP990100656A ARP990100656A AR020054A1 AR 020054 A1 AR020054 A1 AR 020054A1 AR P990100656 A ARP990100656 A AR P990100656A AR P990100656 A ARP990100656 A AR P990100656A AR 020054 A1 AR020054 A1 AR 020054A1
Authority
AR
Argentina
Prior art keywords
adenovirus
composition understanding
virus
virus preparations
composition
Prior art date
Application number
ARP990100656A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR020054A1 publication Critical patent/AR020054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion que contiene virus en una formulacion que contiene un polihidroxi hidrocarburo regulada para mantener un ph en el intervalo de aproximadamente7 a aproximadamente 8,5 a una temperatura en el orden de aproximadamente 2sC a 27sC; preparadosde virus concentrado y purificado y métodos para concentrar ypurificar dichos preparados de virus. Estos virus se utilizan para terapia génica.
ARP990100656A 1998-02-17 1999-02-23 COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS AR020054A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
AR020054A1 true AR020054A1 (es) 2002-04-10

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990100656A AR020054A1 (es) 1998-02-17 1999-02-23 COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS
ARP070104576A AR063314A2 (es) 1998-02-17 2007-10-16 Metodos para purificar preparados de virus
ARP070104577A AR063315A2 (es) 1998-02-17 2007-10-16 Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP070104576A AR063314A2 (es) 1998-02-17 2007-10-16 Metodos para purificar preparados de virus
ARP070104577A AR063315A2 (es) 1998-02-17 2007-10-16 Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus

Country Status (24)

Country Link
EP (4) EP1054955B1 (es)
JP (3) JP4358434B2 (es)
KR (5) KR100912362B1 (es)
CN (2) CN101164623B (es)
AR (3) AR020054A1 (es)
AT (3) ATE341614T1 (es)
AU (1) AU757976B2 (es)
BR (1) BR9908015A (es)
CA (2) CA2723040A1 (es)
CO (1) CO4820440A1 (es)
DE (3) DE69942708D1 (es)
DK (1) DK1054955T3 (es)
ES (2) ES2272053T3 (es)
HU (1) HU226015B1 (es)
ID (1) ID28298A (es)
IL (2) IL137510A0 (es)
MY (1) MY141641A (es)
NO (1) NO20004104L (es)
PE (1) PE20000265A1 (es)
PL (1) PL197747B1 (es)
PT (1) PT1054955E (es)
SK (1) SK11842000A3 (es)
TW (1) TWI232107B (es)
WO (1) WO1999041416A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1977764A1 (en) * 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2399321C (en) * 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A8 (en) * 2000-12-12 2008-01-17 Japan Tobacco Inc Pharmaceutical composition containing an active with a hemolytic action and a surfactant
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
WO2005080556A2 (en) 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
US7851218B2 (en) 2004-12-13 2010-12-14 Schering Corporation Cell lines for production of replication-defective adenovirus
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
PT2007883E (pt) * 2006-04-20 2012-02-17 Wyeth Llc Processos de purificação para o isolamento do vírus da estomatite vesicular purificado de cultura de células
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
CN102459611B (zh) 2009-05-02 2016-11-09 建新公司 神经退行性疾病的基因治疗
BR112012019023B1 (pt) 2010-02-15 2021-12-21 Janssen Vaccines & Prevention B.V. Método para produzir adenovírus recombinante sorotipo 26 (rad26), e, uso de um biorreator
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
CN103492557B (zh) * 2011-04-29 2015-07-29 昂科利蒂克斯生物科技公司 使用凝胶渗透色谱法纯化病毒的方法
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
HUE027839T2 (en) 2012-03-12 2016-11-28 Crucell Holland Bv Recombinant adenoviruses with altered terminals
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
NZ630753A (en) 2012-03-22 2016-12-23 Janssen Vaccines & Prevention Bv Vaccine against rsv
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
JP2017519734A (ja) * 2014-05-28 2017-07-20 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ ウイルスの減少方法
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EP3821906A1 (en) 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
MA52910A (fr) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention Bv Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
JP6683847B2 (ja) 2016-06-20 2020-04-22 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 強力でバランスのとれた双方向性プロモーター
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
CA3073790A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
EP3880243A1 (en) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2020264411A1 (en) * 2019-06-28 2020-12-30 Baxalta Incorporated Adeno-associated virus purification methods
EP4097122A4 (en) 2020-01-31 2024-07-17 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
US20230175012A1 (en) * 2020-03-19 2023-06-08 Trizell Ltd. Temperature-responsive virus storage system
KR20230147156A (ko) 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (es) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
PL186073B1 (pl) 1993-10-25 2003-10-31 Canji Preparat farmaceutyczny, zwłaszcza do terapii genowej
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
TWI232107B (en) 2005-05-11
DE69933433D1 (de) 2006-11-16
KR20010072547A (ko) 2001-07-31
BR9908015A (pt) 2001-04-24
KR100912362B1 (ko) 2009-08-19
CN101164623B (zh) 2012-11-14
CN101164623A (zh) 2008-04-23
EP1526173A2 (en) 2005-04-27
NO20004104D0 (no) 2000-08-16
HUP0100670A2 (hu) 2001-06-28
AR063314A2 (es) 2009-01-21
AU2653899A (en) 1999-08-30
EP1054955A2 (en) 2000-11-29
EP1741777A1 (en) 2007-01-10
HU226015B1 (en) 2008-02-28
AU757976B2 (en) 2003-03-13
IL137510A0 (en) 2001-07-24
DK1054955T3 (da) 2007-01-15
IL137510A (en) 2012-10-31
CO4820440A1 (es) 1999-07-28
CN1297478A (zh) 2001-05-30
AR063315A2 (es) 2009-01-21
KR100862169B1 (ko) 2008-10-09
CN100374551C (zh) 2008-03-12
JP2006166925A (ja) 2006-06-29
DE69942708D1 (de) 2010-10-07
ES2272053T3 (es) 2007-04-16
WO1999041416A3 (en) 1999-11-18
JP2002503484A (ja) 2002-02-05
SK11842000A3 (sk) 2001-05-10
WO1999041416A2 (en) 1999-08-19
PE20000265A1 (es) 2000-04-25
PL197747B1 (pl) 2008-04-30
KR20090038927A (ko) 2009-04-21
KR100918187B1 (ko) 2009-09-22
DE69936948T2 (de) 2008-05-15
HUP0100670A3 (en) 2003-10-28
KR100991683B1 (ko) 2010-11-04
ID28298A (id) 2001-05-10
EP1526173A3 (en) 2005-08-10
HK1028416A1 (en) 2001-02-16
PL342847A1 (en) 2001-07-16
HK1097413A1 (en) 2007-06-22
CA2723040A1 (en) 1999-08-19
NO20004104L (no) 2000-10-17
EP1741777B1 (en) 2010-08-25
DE69936948D1 (de) 2007-10-04
KR20090127947A (ko) 2009-12-14
CA2320419A1 (en) 1999-08-19
ES2290613T3 (es) 2008-02-16
PT1054955E (pt) 2007-01-31
KR101018992B1 (ko) 2011-03-07
ATE478945T1 (de) 2010-09-15
ATE371020T1 (de) 2007-09-15
JP2010213727A (ja) 2010-09-30
MY141641A (en) 2010-05-31
ATE341614T1 (de) 2006-10-15
DE69933433T2 (de) 2007-08-23
EP1526174B1 (en) 2007-08-22
EP1054955B1 (en) 2006-10-04
JP4358434B2 (ja) 2009-11-04
EP1526174A2 (en) 2005-04-27
KR20080065615A (ko) 2008-07-14
EP1526173B1 (en) 2012-11-21
HK1073481A1 (en) 2005-10-07
KR20080065614A (ko) 2008-07-14
CA2320419C (en) 2011-02-08
EP1526174A3 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
AR020054A1 (es) COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS
GB2199328B (en) Use of a 5' untranslated leader sequence of an rna virus to enhance translation
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
ATE236886T1 (de) 2,4-dioxo-imidazolidin-derivate
ATE387492T1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
BR9814340A (pt) Derivados de indol como inibidores de fator xa
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
EA199901031A1 (ru) Производные бензимидазола
TR199902626T2 (xx) Enflamasyon tedavisi i�in ikameli benzopiran t�revleri.
ATE231839T1 (de) Polyaromatische antivirale zusammensetzungen
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
AU2658695A (en) N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors
BR0313455A (pt) modulação "antisense" da expressão de nav1.3
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
BR9807471A (pt) Uso do composto anti-cd40l
AR010565A1 (es) Moleculas de acido nucleico aislados, proteina aislada, formulaciones que las contienen, composicion terapeutica, uso de un compuesto protector y uninhibidor para preparar una composicion terapeutica, metodo para producir una proteina de carboxilesterosa, metodo para identificar compuestos, equipo d
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
NO892125D0 (no) Kombinasjon av angiotensin-omvandlende-enzymhemmere med kaliumkanal-modulatorer samt deres anvendelse i legemidler.
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
BR9801085A (pt) Processo para a preparação de moenomicina a.
DE69739167D1 (de) Zusammensetzungen zur modulierung der länge von telomeren

Legal Events

Date Code Title Description
FG Grant, registration